Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2010

01-09-2010

Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus

Author: Khalid Hussain

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2010

Login to get access

Abstract

Glucokinase is a key enzyme involved in regulating insulin secretion from the pancreatic ß-cell. The unique role of glucokinase in human glucose physiology is illustrated by the fact that genetic mutations in glucokinase can either cause hyperglycaemia or hypoglycaemia. Heterozygous inactivating mutations in glucokinase cause maturity-onset diabetes of the young (MODY), homozygous inactivating in glucokinase mutations result in permanent neonatal diabetes whereas heterozygous activating glucokinase mutations cause hyperinsulinaemic hypoglycaemia
Literature
1.
Middleton RJ. Hexokinases and glucokinases. Biochem Soc Trans. 1990;18(2):180–3.PubMed
2.
Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes. 2006;55(1):1–12.CrossRefPubMed
3.
Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res. 2001;56:195–217.CrossRefPubMed
4.
Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes. 2002;51 Suppl 3:S394–404.CrossRefPubMed
5.
Matschinsky FM, Glaser B, Magnuson MA. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes. 1998;47(3):307–15.CrossRefPubMed
6.
Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009;66(1):27–42. Review.CrossRefPubMed
7.
Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes. 2003;52(9):2433–40.CrossRefPubMed
8.
Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301:370–3.CrossRefPubMed
9.
Koranyi LI, Tanizawa Y, Welling CM, Rabin DU, Permutt MA. Human islet glucokinase gene. Isolation and sequence analysis of full-length cDNA. Diabetes. 1992;41(7):807–11.CrossRefPubMed
10.
Iynedjian PB, Möbius G, Seitz HJ, Wollheim CB, Renold AE. Tissue-specific expression of glucokinase: identification of the gene product in liver and pancreatic islets. Proc Natl Acad Sci U S A. 1986;83(7):1998–2001.CrossRefPubMed
11.
Liang Y, Jetton TL, Zimmerman EC, Najafi H, Matschinsky FM, Magnuson MA. Effects of alternate RNA splicing on glucokinase isoform activities in the pancreatic islet, liver, and pituitary. J Biol Chem. 1991;266(11):6999–7007.PubMed
12.
Gasa R, Fabregat ME, Gomis R. The role of glucose and its metabolism in the regulation of glucokinase expression in isolated human pancreatic islets. Biochem Biophys Res Commun. 2000;268(2):491–5.CrossRefPubMed
13.
Iynedjian PB, Pilot PR, Nouspikel T, Milburn JL, Quaade C, Hughes S, et al. Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc Natl Acad Sci U S A. 1989;86(20):7838–42.CrossRefPubMed
14.
Arden C, Harbottle A, Baltrusch S, Tiedge M, Agius L. Glucokinase is an integral component of the insulin granules in glucose-responsive insulin secretory cells and does not translocate during glucose stimulation. Diabetes. 2004;53(9):2346–52.CrossRefPubMed
15.
Iynedjian PB. Mammalian glucokinase and its gene. Biochem J. 1993;293:1–13.PubMed
16.
Fernandez-Mejia C, Vega-Allende J, Rojas-Ochoa A, Rodriguez-Dorantes M, Romero-Navarro G, Matschinsky FM, et al. Cyclic adenosine 3', 5'-monophosphate increases pancreatic glucokinase activity and gene expression. Endocrinology. 2001;142(4):1448–52.CrossRefPubMed
17.
Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell. 1995;83(1):69–78.CrossRefPubMed
18.
Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic ß cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274:305–15.CrossRefPubMed
19.
Shiota M, Postic C, Fujimoto Y, Jetton TL, Dixon K, Pan D, et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes. 2001;50:622–9.CrossRefPubMed
20.
Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998;338(4):226–30.CrossRefPubMed
21.
Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes. 2002;51(4):1240–6.CrossRefPubMed
22.
Dullaart RP, Hoogenberg K, Rouwe CW, Stulp BK. Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene. J Intern Med. 2004;255(1):143–5.CrossRefPubMed
23.
Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J, et al. Severe Persistent Hyperinsulinemic Hypoglycemia due to a De Novo Glucokinase Mutation. Diabetes. 2004;53(8):2164–8.CrossRefPubMed
24.
Christesen HB, Tribble ND, Molven A, Siddiqui J, Sandal T, Brusgaard K, et al. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol. 2008;159(1):27–34.CrossRefPubMed
25.
Barbetti F, Cobo-Vuilleumier N, Dionisi-Vici C, Toni S, Ciampalini P, Massa O, et al. Opposite clinical phenotypes of glucokinase disease: description of a novel activating mutation and contiguous inactivating mutations in human glucokinase(GCK) Gene. Mol Endocrinol. 2009;23(12):1983–9.CrossRefPubMed
26.
Kassem S, Heyman M, Glaser B, Bhandari S, Motaghedi R, Maclaren NK, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med. 2010;362(14):1348–50.CrossRefPubMed
27.
Meissner T, Marquard J, Cobo-Vuilleumier N, Maringa M, Rodríguez-Bada P, García-Gimeno MA, et al. Diagnostic Difficulties in Glucokinase Hyperinsulinism. Horm Metab Res. 2008 Dec 3.
28.
Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, et al. Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism due to glucokinase activating mutations. Diabetes. 2009;58(6):1419–27.CrossRefPubMed
29.
Pal P, Miller BG. Activating mutations in the human glucokinase gene revealed by genetic selection. Biochemistry. 2009;48(5):814–6.CrossRefPubMed
30.
Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J, et al. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabet Med. 2007;24(12):1393–9. Epub 2007 Nov 1.
31.
Christesen HB, Brusgaard K, Beck Nielsen H, Brock Jacobsen B. Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: Hypoglycaemia unawareness and attacks. Clin Endocrinol (Oxf). 2008;68(5):747–55.CrossRef
32.
Davis EA, Cuesta-Muñoz A, Raoul M, Buettger C, Sweet I, Moates M, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia. 1999;42(10):1175–86.CrossRefPubMed
33.
Van de Bunt M, Edghill ML, Hussain K, Ellard S, Gloyn A. Gene duplications resulting in over expression of glucokinase are not a common cause of hypoglycaemia of infancy in humans. Mol Genet Metab. 2008;94(2):268–9.CrossRefPubMed
34.
Vaxillaire M, Samson C, Cavé H, Metz C, Froguel P, Polak M. Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France. Diabetologia. 2002;45(3):454–5.CrossRefPubMed
35.
Gloyn AL, Ellard S, Shield JP, Temple IK, Mackay DJ, Polak M, et al. Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. Diabetologia. 2002;45(2):290.CrossRefPubMed
36.
Njølstad PR, Søvik O, Cuesta-Muñoz A, Bjørkhaug L, Massa O, Barbetti F, et al. GI. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001;344(21):1588–92.CrossRefPubMed
37.
Njølstad PR, Sagen JV, Bjørkhaug L, Odili S, Shehadeh N, Bakry D, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes. 2003;52(11):2854–60.CrossRefPubMed
38.
Porter JR, Shaw NJ, Barrett TG, Hattersley AT, Ellard S, Gloyn AL. Permanent neonatal diabetes in an Asian infant. J Pediatr. 2005;146(1):131–3.CrossRefPubMed
39.
Turkkahraman D, Bircan I, Tribble ND, Akcurin S, Ellard S, Gloyn AL. Permanent Neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. J Pediatr. 2008;153(1):122–6.CrossRefPubMed
40.
Rubio-Cabezas O, Diaz GF, Aragones A, Argente J, Campos-Barros A. Permanent neonatal diabetes caused by a homozygous nonsense mutation in the glucokinase gene. Pediatr Diabetes. 2008;9(3 Pt 1):245–9.CrossRefPubMed
41.
Bennett K, James C, Mutair A, Al-Shaikh H, Sinani A, Hussain K. Four novel cases of permanent neonatal diabetes mellitus caused by homozygous mutations in the glucokinase gene. Pediatr Diabetes (in press)
Metadata
Title
Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus
Author
Khalid Hussain
Publication date
01-09-2010
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2010
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-010-9147-z

Other articles of this Issue 3/2010

Reviews in Endocrine and Metabolic Disorders 3/2010 Go to the issue

OriginalPaper

6q24 transient neonatal diabetes

OriginalPaper

Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene

OriginalPaper

Role of 18F-DOPA PET/CT imaging in congenital hyperinsulinism

OriginalPaper

Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11

OriginalPaper

Congenital Hyperinsulinism due to mutations in HNF4A and HADH

OriginalPaper

The hyperinsulinism/hyperammonemia syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits